Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134369
Abstract: Introduction: Identifying prior therapy exposures that affect the patient or their peripheral blood mononuclear cell (PBMC) material is one strategy to optimize outcomes to CAR T cell therapy. Alkylating agents commonly used in multiple myeloma… read more here.
Keywords: company; current equity; traded company; publicly traded ... See more keywords
Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134378
Abstract: Background: Patients (pts) with relapsed and refractory multiple myeloma (RRMM) experience unsatisfactory outcomes with established treatment modalities. In the pivotal phase 2 KarMMa study (NCT03361748), idecabtagene vicleucel (ide-cel, bb2121) demonstrated frequent, deep, and durable responses… read more here.
Keywords: company; current equity; traded company; publicly traded ... See more keywords
Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-135921
Abstract: Introduction: Treatment options for acute myeloid leukaemia (AML) patients have increased in recent years as several novel targeted medications for AML patients have been introduced. The aim of this study was to identify the integration… read more here.
Keywords: aml patients; holder publicly; equity holder; current equity ... See more keywords